IXICO supported a 6-year, multinational clinical trial involving over 250 participants across more than 220 sites, delivering precision neuroimaging to assess Parkinson’s disease biomarkers.
We use cookies to understand more about who's visiting our website, and, where we can, to provide you with a more tailored service. You can change your cookie settings at any time.